Invasive aspergillosis: results of multicenter study
https://doi.org/10.17650/1818-8346-2014-9-2-13-19
Abstract
We present the results of a multicenter study of 445 patients with “proven” and “probable” invasive aspergillosis (EORTC/MSG, 2008). Invasive aspergillosis usually occurs in patients with hematological malignancies (88 %), main underlying diseases were acute myeloid and acute lymphoblastic leukemia. The risk factors: prolonged agranulocytosis (64 %), cytostatic chemotherapy (57 %), corticosteroid treatment (45 %), and allogeneic hematopoietic stem cells transplantation (29 %). The pathogens – A. fumigatus (42 %), A. niger (33 %), and A. flavus (21 %). The main site of infection were lungs (86 %). 12 week overall survival was 83 %. Bronchoscopy use for the early diagnosis (p = 0.01), adequate
therapy with voriconazole (p = 0.002) and secondary antifungal prophylaxis (p = 0.0003) were positive prognostic factors for survival of patients with invasive aspergillosis.
About the Authors
N. N. Klimko
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology
Russian Federation
Russian Federation
O. V. Shadrivova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
S. N. Khostelidi
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
E. A. Desyatik
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
Yu. V. Borzova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
R. M. Chernopyatova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
E. V. Shagdileeva
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
A. G. Volkova
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
M. O. Popova
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
I. S. Zyuzgin
Leningrad Regional Hospital, Saint Petersburg
Russian Federation
Russian Federation
O. S. Ruzhinskaya
Leningrad Regional Hospital, Saint Petersburg
Russian Federation
Russian Federation
O. Ye. Ryabykina
Leningrad Regional Hospital, Saint Petersburg
Russian Federation
Russian Federation
N. V. Medvedeva
Municipal Hospital № 31, Saint Petersburg
Russian Federation
Russian Federation
A. S. Kolbin
Children Municipal Hospital № 1, Saint Petersburg
Russian Federation
Russian Federation
E. G. Boychenko
Children Municipal Hospital № 1, Saint Petersburg
Russian Federation
Russian Federation
T. S. Bogomolova
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
S. M. Ignatieva
P.N. Kashkin Research Institute of Medical Mycology and Department of Clinical Mycology, Allergy and Immunology I. I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, Saint Petersburg
Russian Federation
Russian Federation
L. S. Zubarovskaya
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
B. V. Afanasiev
Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. De Pauw B., Walsh T. J., Donnelly J. P. et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC / MSG) Consensus Group. Clinical Infectious Diseases 2008;46(12):1813–21.
2. Kousha M., Tadi R., Soubani A. O. Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011;20(21):156–72.
3. Попова М. О., Зубаровская Л. С., Климко Н. Н., Афанасьев Б. В. Инвазивные микозы при трансплантации гемопоэтических стволовых клеток. Тер архив 2012;7:50–7.
4. Baddley J. W. Clinical risk factors for invasive aspergillosis. ISHAM Medical Mycology 2011;49(l):7–12.
5. Климко Н. Н. Микозы: диагностика и лечение. Руководство для врачей, 2‑е издание, 2008. С. 206.
6. Kleinkauf N., Verweij P. E., Arendrup M. C. et al. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species. Technical report of the European Centre for Disease Prevention and Control (ECDC) – 2013. Stockholm: ECDC; 2013. Pp. 4–6.
7. Singh N., Husain S.; AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009;9(4):S180–91.
8. Zmeili O., Soubani A. Pulmonary aspergillosis: a clinical update. OJM 2007;100(6):317–34.
9. Lortholary O., Gangneux J.‑P., Sitbon K. et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect 2011;17(12):1882–9.
10. Nicolle M. C., Bénet T., Thiebaut A. et al. Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica 2011;96(11):1685–91.
11. Pagano L., Caira M., Candoni A. et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010;95(4):644–65.
12. Drgona L., Colita A., Klimko N. et al. Triggers for driving treatment of at-risk patients with invasive fungal disease. J Antimicrob Chemother 2013;68(3):17–24.
13. Herbrecht R., Denning D. W., Patterson T. F. at al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408–15.
14. Противогрибковая профилактика при трансплантации аллогенных гемопоэтических стволовых клеток. Российские национальные рекомендации (под ред. Л. С. Зубаровской, Н. Н. Климко, Г. А. Клясовой, А. А. Масчана). М., 2010.
Review
For citations:
Klimko N.N., Shadrivova O.V., Khostelidi S.N., Desyatik E.A., Borzova Yu.V., Chernopyatova R.M., Shagdileeva E.V., Volkova A.G., Popova M.O., Zyuzgin I.S., Ruzhinskaya O.S., Ryabykina O.Ye., Medvedeva N.V., Kolbin A.S., Boychenko E.G., Bogomolova T.S., Ignatieva S.M., Zubarovskaya L.S., Afanasiev B.V. Invasive aspergillosis: results of multicenter study. Oncohematology. 2014;9(2):13-19. (In Russ.) https://doi.org/10.17650/1818-8346-2014-9-2-13-19
Views:
10225
Email this article 